Insulin Resistance
Conditions
Brief summary
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
Detailed description
The investigators have previously demonstrated that infusion of the pentapeptide during hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to maintain stable hyperglycemia without any significant differences in insulin or glucagon secretion. The present study's aim is to examine whether this also occurs in humans. It may be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers glucose infusion rate during the peptide infusion will be compared to the glucose infusion rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over design(mg/kg/min).
Interventions
DRUGLast 5 amino acids of GLP-1
To examine insulinomimetic properties of LVKGR
DRUGplacebo saline
Sponsors
ICON plc
Massachusetts General Hospital
National Institute on Aging (NIA)
Elahi, Dariush, PhD
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI 18.5-25; * 33-38
Exclusion criteria
* T2D * T1D * Hypoglycemic agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of VTC-G15 on whole body glucose metabolism in man will be assessed by comparison of amont of glucose infusion during the peptide infusion compared to amount of infusion during placebo infusion (saline) mg/kg/min. | one year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| THe effect of VTC-G15(A pentapeptide cleavage product of GLP-1) on whole body glucose metabolism in man. | one year | changes in insulin or glucagon release. |
Countries
United States
Contacts
Primary ContactDariush E;ahi, PhD
Backup ContactDennis A Ruff, MD
Outcome results
None listed